Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Theravance Biopharma (TBPH) Leases (2019 - 2025)

Theravance Biopharma (TBPH) has disclosed Leases for 7 consecutive years, with $25.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Leases fell 13.24% to $25.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.4 million, a 13.24% decrease, with the full-year FY2024 number at $28.4 million, changed N/A from a year prior.
  • Leases was $25.4 million for Q3 2025 at Theravance Biopharma, down from $26.5 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $42.5 million in Q1 2021 to a low of $25.4 million in Q3 2025.
  • A 5-year average of $35.6 million and a median of $38.5 million in 2023 define the central range for Leases.
  • Peak YoY movement for Leases: fell 0.37% in 2023, then fell 22.44% in 2025.
  • Theravance Biopharma's Leases stood at $40.7 million in 2021, then fell by 1.45% to $40.1 million in 2022, then fell by 6.35% to $37.6 million in 2023, then decreased by 24.54% to $28.4 million in 2024, then fell by 10.24% to $25.4 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Leases are $25.4 million (Q3 2025), $26.5 million (Q2 2025), and $27.4 million (Q1 2025).